SynAct Pharma (SYNACT) Life Science Summit 2025 summary

Strategic focus and development programs

• Advancing a dual development strategy for resomelagon (AP1189) in newly diagnosed rheumatoid arthritis and as host-directed therapy for severe viral infections.

• Phase IIB trial in rheumatoid arthritis targets newly diagnosed patients with high disease activity and poor prognosis factors.

• Host-directed therapy program addresses hyper-inflammatory responses in viral infections, with ongoing studies in respiratory insufficiency and dengue.

• Pipeline includes additional peptide-based projects and plans for business development partnerships for phase III advancement.

Clinical progress and upcoming milestones

• Over 80% of patients recruited for the 240-patient phase IIB rheumatoid arthritis study, with key results expected in the first half of next year.

• Clinical studies in viral infections, including COVID and dengue, are ongoing, with a dengue study set to begin in Brazil during the next epidemic season.

• Major data readouts and business development activities are anticipated in 2025, with continued updates on respiratory insufficiency studies.

• Funding is secured through 2027, supporting ongoing and planned clinical programs.

Scientific approach and competitive landscape

• Resomelagon is a first-in-class, non-suppressive therapy that modulates immune response by shifting macrophage phenotype to promote inflammation resolution.

• Therapy aims to reduce reliance on glucocorticoids and postpone second-line treatments, potentially improving patient outcomes.

• Resolution therapy is positioned as a novel, patient-friendly oral treatment, with limited direct competition and growing industry recognition.